Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article analyzes various cases of weak or low-dose endocrine effects in laboratory animals and highlights challenges in data interpretation due to variability among controls, but reports no new experimental findings.

This review discusses attempts to confirm low-dose effects in rodent endocrine studies and reports no findings; variability in control groups hinders demonstrating weak effects.

This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.

The authors concluded that incorporating routine endocrinology consultations into transplant care could address CNI-related endocrine toxicities, but prospective studies are needed to assess the impact on graft and patient survival.

This study found that patients receiving immune checkpoint inhibitors who have a history of psoriasis are at a higher risk for developing gastrointestinal and endocrine toxicities within one year compared to those without psoriasis.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

This review describes the toxicities associated with calcineurin inhibitors, used in kidney transplantation, which include nephrotoxicity, cardiovascular and endocrine issues, and quality of life impacts, without reporting new clinical results.

This review highlighted that targeted cancer therapies, while generally causing mild toxicities that can be managed, also pose risks of rare but serious side effects like pneumonitis and cardiotoxicities, emphasizing the need for vigilant monitoring and management to ensure patient safety.

This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.

This study found that endocrine therapy for breast cancer is associated with a pattern of hair loss similar to androgenetic alopecia, negatively impacting quality of life despite mild severity.

This review discusses the various causes of hirsutism other than PCOS, emphasizing the importance of distinguishing potentially life-threatening conditions like androgen-secreting tumors from more benign causes; it reports no new clinical findings.

In this publication, a collaborative group reviewed the role of dermocosmetics in cancer care and formulated recommendations for using these products to manage skin toxicities and minimize treatment interruptions associated with cancer therapies.

This review highlights the possible impact of side effects from endocrine therapy on quality of life, emphasizing that these can lead to poor adherence and early treatment discontinuation in patients with hormone receptor positive early breast cancer, potentially worsening survival outcomes.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This paper reviews seven major systemic causes of hair loss and provides a clinical evaluation framework but reports no new experimental results.

The document explains various skin conditions in cats and how to diagnose and treat them.

This article provides an overview of conditions that can cause hair loss in dogs and cats and offers guidance on diagnostic approaches, but it presents no new research findings.

These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

This review discusses common skin toxicities from cancer treatments and offers management strategies, particularly for regions like Australia and New Zealand with high UV exposure.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

This study found that breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapy experienced more pronounced vertex hair loss and were less responsive to minoxidil treatment compared to those on endocrine monotherapy.

This study found that higher prenatal and early childhood lead exposure may be associated with delayed pubertal development in girls, but not in boys, in Mexico City.

This study found that oral minoxidil improved hair density in women experiencing late alopecia due to chemotherapy and/or endocrine therapy, with 74% showing clinical improvement and statistically significant increases in hair shaft density reported in those assessed with trichoscopy.

This paper reviews various causes of alopecia in cancer patients and highlights the importance of understanding these mechanisms for effective management, but reports no new findings.

This review discusses the role of mental healthcare in managing sexual side effects of prostate cancer radiotherapy and highlights the importance of patient education and psychological support for improved quality of life.